Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 151 AL 165

Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy

Liu J, Yang B, Ke J, Li W, Suen WC.

Drugs Aging. 2016 Oct;33(10):685-697. doi: 10.1007/s40266-016-0406-x.

The amyloid cascade hypothesis: are we poised for success or failure?

Karran E, De Strooper B.

J Neurochem. 2016 Oct;139 Suppl 2:237-252. doi: 10.1111/jnc.13632. Epub 2016 Jun 3.

Treatment of epilepsy for people with Alzheimer's disease

Liu J, Wang LN, Wu LY, Wang YP.

Cochrane Database Syst Rev. 2016 Nov 2;11(11):CD011922. doi: 10.1002/14651858.CD011922.pub2.

Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy

Sharma HS, Muresanu DF, Sharma A.

Neurodegener Dis Manag. 2016 Dec;6(6):453-456. doi: 10.2217/nmt-2016-0037. Epub 2016 Nov 9.

The road to restoring neural circuits for the treatment of Alzheimer's disease

Canter RG, Penney J, Tsai LH.

Nature. 2016 Nov 10;539(7628):187-196. doi: 10.1038/nature20412.

Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review

Wang ZY, Liu JG, Li H, Yang HM.

Am J Chin Med. 2016;44(8):1525-1541. doi: 10.1142/S0192415X16500853. Epub 2016 Nov 16.

Pharmacotherapies for sleep disturbances in dementia

McCleery J, Cohen DA, Sharpley AL.

Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

Promise of new Alzheimer's drug is dashed after lack of evidence

Hawkes N.

BMJ. 2016 Nov 24;355:i6362. doi: 10.1136/bmj.i6362.

Sixty seconds on . . . solanezumab

Hawkes N.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish"

Choi SH, Kim YH, Quinti L, Tanzi RE, Kim DY.

Mol Neurodegener. 2016 Dec 9;11(1):75. doi: 10.1186/s13024-016-0139-7.

Development and Structural Modification of BACE1 Inhibitors

Gu T, Wu WY, Dong ZX, Yu SP, Sun Y, Zhong Y, Lu YT, Li NG.

Molecules. 2016 Dec 22;22(1):4. doi: 10.3390/molecules22010004.

Solanezumab and the amyloid hypothesis for Alzheimer's disease

Le Couteur DG, Hunter S, Brayne C.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies

Rygiel K.

Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias